secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zivo Bioscience, Inc. (ZIVO)
CIK:        0001101026
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0001654954-24-007455
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 5.02, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zivo Bioscience adopts new Director Equity Plan, boosts share reserves, grants equity to directors and officers
--------------------------------------------------------------------------------

- Adopted 2024 Director Equity Plan (875k shares, auto-increase 5%/yr). Director cash fee raised from $40k to $50k, eligible for restricted stock/RSUs.
- Amended 2021 Plan reserve from 166,666 to 1,000,000 shares; terminated 2019 Plan.
- Granted 127,364 restricted shares to directors replacing cancelled options; additional 261,619 shares for unpaid 2023 fees.
- Issued 1,031,425 stock options to officers: CEO John Payne (217,431), CFO Keith Marchiando (444,498) replacing prior options and cash bonus.
- Total unregistered securities issued: 426,671 common shares and options for 1,031,425 shares; outstanding shares at 3,278,807.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1101026/000165495424007455/0001654954-24-007455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1101026/000165495424007455/zivo_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-007455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer